9 Meters Biopharma, Inc.

Equities

NMTRQ

US6544052086

Investment Holding Companies

Market Closed - OTC Markets 07:03:58 08/07/2024 pm IST 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for 9 Meters Biopharma, Inc. 0.00% 0.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Tech in Focus on -2- DJ
Bidding Procedure Approved for 9 Meters Biopharma, Inc. CI
Amendment to Motion for Asset Sale Filed by 9 Meters Biopharma, Inc. CI
Motion for Asset Sale Filed by 9 Meters Biopharma, Inc. CI
North American Morning Briefing : Stocks Look to -2- DJ
Motion for Asset Sale Filed by 9 Meters Biopharma, Inc. CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Mood Seen Buoyed -2- DJ
North American Morning Briefing : Apple's China Conflict, Rate Hike Fears Continue to Weigh DJ
North American Morning Briefing : Jobs Report Eyed for Hiring Slowdown DJ
North American Morning Briefing : Investors Await Powell's Jackson Hole Speech DJ
North American Morning Briefing : China Trouble Hits Sentiment DJ
North American Morning Briefing : Stock Futures -2- DJ
Illumina cuts annual profit forecast as biotech funding woes linger RE
Illumina cuts annual profit forecast RE
9 Meters Biopharma, Inc.(OTCPK:NMTR.Q) dropped from NASDAQ Composite Index CI
9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from S&P TMI Index CI
Drug developer 9 Meters Biopharma files for bankruptcy protection RE
9 Meters Biopharma, Inc. Filed for Bankruptcy CI
9 Meters Biopharma Names Bethany Sensenig Interim Chief Executive; Shares Fall MT
9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome CI
9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President CI
9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as Chief Executive Officer CI
9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO CI
Citigroup Adjusts 9 Meters Biopharma Price Target to $0.75 From $1.70, Maintains Neutral Rating MT
Chart 9 Meters Biopharma, Inc.
More charts
9 Meters Biopharma, Inc. has ceased operations. The Company has filed a voluntary petition for relief under provisions of Chapter 7 of Title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the Eastern District of North Carolina.
More about the company
  1. Stock Market
  2. Equities
  3. NMTRQ Stock
  4. News 9 Meters Biopharma, Inc.
  5. Truist Downgrades 9 Meters Biopharma to Hold From Buy